- Home
- GLPG vs ASH Comparison
GLPG vs ASH Comparison
Compare GLPG & ASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- ASH
- Stock Information
- Founded
- GLPG 1999
- ASH 1924
- Country
- GLPG Belgium
- ASH United States
- Employees
- GLPG N/A
- ASH N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- ASH Specialty Chemicals
- Sector
- GLPG Health Care
- ASH Consumer Discretionary
- Exchange
- GLPG Nasdaq
- ASH Nasdaq
- Market Cap
- GLPG 2.1B
- ASH 2.2B
- IPO Year
- GLPG 2005
- ASH N/A
- Fundamental
- Price
- GLPG $29.89
- ASH $50.74
- Analyst Decision
- GLPG Hold
- ASH Buy
- Analyst Count
- GLPG 4
- ASH 7
- Target Price
- GLPG $30.00
- ASH $60.50
- AVG Volume (30 Days)
- GLPG 209.6K
- ASH 692.7K
- Earning Date
- GLPG 11-05-2025
- ASH 11-04-2025
- Dividend Yield
- GLPG N/A
- ASH 3.27%
- EPS Growth
- GLPG N/A
- ASH N/A
- EPS
- GLPG N/A
- ASH N/A
- Revenue
- GLPG $323,674,692.00
- ASH $1,824,000,000.00
- Revenue This Year
- GLPG $1.77
- ASH $3.18
- Revenue Next Year
- GLPG $0.44
- ASH $3.72
- P/E Ratio
- GLPG N/A
- ASH N/A
- Revenue Growth
- GLPG 5.43
- ASH N/A
- 52 Week Low
- GLPG $22.36
- ASH $45.21
- 52 Week High
- GLPG $37.78
- ASH $88.89
- Technical
- Relative Strength Index (RSI)
- GLPG 34.46
- ASH 56.23
- Support Level
- GLPG $30.92
- ASH $49.54
- Resistance Level
- GLPG $31.85
- ASH $50.85
- Average True Range (ATR)
- GLPG 0.81
- ASH 1.32
- MACD
- GLPG -0.27
- ASH 0.06
- Stochastic Oscillator
- GLPG 1.70
- ASH 85.38
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About ASH Ashland Inc.
Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.